Akbar Armaan F, Zhou Alice L, Ruck Jessica M, Kilic Ahmet, Cedars Ari M
Division of Cardiac Surgery, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland.
Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland.
J Heart Lung Transplant. 2024 Oct;43(10):1691-1700. doi: 10.1016/j.healun.2024.06.005. Epub 2024 Jun 17.
Use of donation after circulatory death (DCD) and hepatitis C virus (HCV) positive donors in heart transplantation have increased the donor pool. Given poor waitlist outcomes in the adult congenital heart disease (ACHD) population, we investigated waitlist outcomes associated with willingness to consider DCD and HCV+ offers and post-transplant outcomes following HCV+ and DCD transplantation for these candidates.
Using the United Network for Organ Sharing database, we identified adult ACHD candidates and recipients listed or transplanted, respectively, between 01/01/2016 and 09/30/2023 for the HCV analysis and between 12/01/2019 and 09/30/2023 for the DCD analysis. Among candidates, we compared the cumulative incidence of transplant, with waitlist death/deterioration as a competing risk, by willingness to consider HCV+ and DCD offers. Among recipients of HCV+ (vs HCV-) and DCD (vs brain death [DBD]) transplants, we compared perioperative outcomes and post-transplant survival.
Of 1,436 ACHD candidates from 01/01/2016 to 09/30/2023, 37.0% were willing to consider HCV+ heart offers. Of 886 ACHD candidates from 12/01/2019 to 09/30/2023, 15.5% were willing to consider DCD offers. On adjusted analysis, willingness to consider HCV+ offers was associated with 84% increased likelihood of transplant, and willingness to consider DCD offers was associated with 56% increased likelihood of transplant. Of 904 transplants between 01/01/2016 and 09/30/2023, 6.4% utilized HCV+ donors, and of 540 transplants between 12/01/2019 and 09/30/2023, 6.9% utilized DCD donors. Recipients of HCV+ (vs HCV-) and DCD (vs DBD) heart transplants had similar likelihood of perioperative outcomes and 1-year survival.
ACHD candidates who were willing to consider HCV+ and DCD offers were more likely to be transplanted and had similar post-transplant outcomes compared to recipients of HCV- and DBD organs.
在心脏移植中使用心脏死亡后器官捐献(DCD)和丙型肝炎病毒(HCV)阳性供体增加了供体库。鉴于成人先天性心脏病(ACHD)人群在等待名单上的预后较差,我们调查了与考虑DCD和HCV阳性供体意愿相关的等待名单预后,以及这些候选者接受HCV阳性和DCD移植后的移植后预后。
利用器官共享联合网络数据库,我们分别确定了在2016年1月1日至2023年9月30日期间登记或接受移植的成年ACHD候选者和受者用于HCV分析,以及在2019年12月1日至2023年9月30日期间用于DCD分析。在候选者中,我们根据考虑HCV阳性和DCD供体的意愿,比较了移植的累积发生率,并将等待名单死亡/病情恶化作为竞争风险。在HCV阳性(与HCV阴性相比)和DCD(与脑死亡[DBD]相比)移植的受者中,我们比较了围手术期结局和移植后生存率。
在2016年1月1日至2023年9月30日的1436名ACHD候选者中,37.0%愿意考虑接受HCV阳性心脏供体。在2019年12月1日至2023年9月30日的886名ACHD候选者中,15.5%愿意考虑接受DCD供体。经调整分析,考虑HCV阳性供体的意愿与移植可能性增加84%相关,考虑DCD供体的意愿与移植可能性增加